AMY1B

Across TCGA pan-cancer cohorts, AMY1B Mutation is linked to patient survival in 1 of 34 cancer types, making it a survival-associated AMY1B data layer compared with 15 for mass-spec protein.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher AMY1B Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated AMY1B expression acts as an unfavorable survival marker.

BLCA are the cancer types where AMY1B Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BLCA	OS	Median	All	0.158	0.720	<.001	48	view →

Pink = unfavorable, green = favorable. Showing the 1 strongest of 1 lineages.

AMY1B–BLCA (OS)

Open the BLCA breakdown →